Sei Investments Co. Sells 2,572 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Sei Investments Co. lowered its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 2.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,119 shares of the company’s stock after selling 2,572 shares during the quarter. Sei Investments Co. owned about 0.06% of Revolution Medicines worth $4,204,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. increased its position in shares of Revolution Medicines by 11.1% in the fourth quarter. American Century Companies Inc. now owns 641,646 shares of the company’s stock worth $28,066,000 after purchasing an additional 64,238 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Revolution Medicines in the 4th quarter worth $186,000. Virtu Financial LLC purchased a new stake in shares of Revolution Medicines during the 4th quarter valued at $272,000. Teacher Retirement System of Texas lifted its holdings in shares of Revolution Medicines by 19.6% during the 4th quarter. Teacher Retirement System of Texas now owns 34,632 shares of the company’s stock worth $1,515,000 after acquiring an additional 5,667 shares during the last quarter. Finally, Xponance Inc. grew its position in Revolution Medicines by 21.4% in the fourth quarter. Xponance Inc. now owns 12,127 shares of the company’s stock worth $530,000 after acquiring an additional 2,140 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 3,058 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the sale, the chief operating officer now owns 153,533 shares in the company, valued at approximately $5,993,928.32. This represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares of the company’s stock, valued at $4,489,834.24. The trade was a 1.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,660 shares of company stock valued at $650,406. 8.00% of the stock is currently owned by company insiders.

Revolution Medicines Trading Up 2.9 %

Revolution Medicines stock opened at $34.60 on Thursday. Revolution Medicines, Inc. has a 1-year low of $29.55 and a 1-year high of $62.40. The firm has a market cap of $6.43 billion, a P/E ratio of -9.64 and a beta of 1.46. The firm has a 50-day moving average of $39.97 and a 200-day moving average of $45.42.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on RVMD shares. Wedbush reaffirmed an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, February 27th. Stifel Nicolaus cut their target price on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday. HC Wainwright lifted their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Needham & Company LLC cut their price objective on shares of Revolution Medicines from $60.00 to $59.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Finally, UBS Group lifted their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Revolution Medicines currently has an average rating of “Buy” and a consensus target price of $65.23.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.